{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:00:17Z","timestamp":1787065217265,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd013817","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000}}],"reference-count":103,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013817.pub2","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T06:52:13Z","timestamp":1654843933000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension"],"prefix":"10.1002","volume":"2022","author":[{"given":"Josefine","family":"Clement Freiberg","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology; University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"von Spreckelsen","sequence":"additional","affiliation":[{"name":"Department of Drug Design and Pharmacology; University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Kolko","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Department of Drug Design and Pharmacology; Copenhagen University Hospital, University of Copenhagen; Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Azuara-Blanco","sequence":"additional","affiliation":[{"name":"Centre for Public Health; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"10.1002\/14651858.CD013817.pub2-BIB0001|cit1","unstructured":"Study of netarsudil ophthalmic solution in Japanese\/Japanese-American subjects with open-angle glaucoma or ocular hypertension clinicaltrials.gov\/ct2\/show\/results\/NCT03310580"},{"issue":"4","key":"10.1002\/14651858.CD013817.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s12325-021-01634-9","article-title":"Phase\u00a02 randomized clinical study of netarsudil ophthalmic solution in Japanese patients with primary open-angle glaucoma or ocular hypertension","volume":"38","author":"Araie","year":"2021","journal-title":"Advanced Therapies"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0003|cit3","unstructured":"Efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan clinicaltrials.gov\/ct2\/show\/NCT03844945"},{"issue":"4","key":"10.1002\/14651858.CD013817.pub2-BIB0004|cit4","first-page":"1620","article-title":"Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase 3 MERCURY-1 and -2","volume":"37","author":"Asrani","year":"2020","journal-title":"Advanced Therapeutics"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2019.06.016","article-title":"Netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial","volume":"207","author":"Asrani","year":"2019","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD013817.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ogla.2020.05.008","article-title":"One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: Phase 3, randomized MERCURY-1 study","volume":"3","author":"Brubaker","year":"2020","journal-title":"Ophthalmology Glaucoma"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0007|cit7","unstructured":"Drug approval package: rocklatan ophthalmic solution www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/208259Orig1s000TOC.cfm"},{"issue":"2","key":"10.1002\/14651858.CD013817.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","article-title":"Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure","volume":"122","author":"Bacharach","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD013817.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10384-018-0599-0","article-title":"Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin\/timolol fixed combination therapy or adding ripasudil","volume":"62","author":"Inoue","year":"2018","journal-title":"Japanese Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0011|cit11","first-page":"9","article-title":"Long-term safety and ocular hypotensive efficacy of netarsudil ophthalmic solution: the ROCKET-2 study","volume":"59","author":"Serle","year":"2018","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0013|cit13","unstructured":"Rhopressa (netarsudil) ophthalmic solution www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208254Orig1s000TOC.cfm"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002.","article-title":"Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study","volume":"204","year":"2019","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD013817.pub2-BIB0015|cit15","first-page":"ARVO E","article-title":"A double-masked, randomized, parallel study of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patients with elevated intraocular pressure (ROCKET-4)","volume":"58","author":"Khouri","year":"2017","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD013817.pub2-BIB0016|cit16","first-page":"ARVO E","article-title":"Fixed dose combination of AR-13324 and latanoprost (PG324): a double-masked, randomized, controlled study in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)","volume":"56","author":"Dubiner","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD013817.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bjophthalmol-2015-306778","article-title":"Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension","volume":"100","author":"Lewis","year":"2016","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0018|cit18","unstructured":"Study assessing safety and efficacy of PG324 ophthalmic solution in patients with elevated intraocular pressure clinicaltrials.gov\/ct2\/show\/NCT02057575"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0019|cit19","unstructured":"Study of netarsudil (AR-13324) ophthalmic solution in patients with glaucoma or ocular hypertension clinicaltrials.gov\/ct2\/show\/NCT02246764"},{"issue":"8","key":"10.1002\/14651858.CD013817.pub2-BIB0020|cit20","first-page":"ARVO E","article-title":"Ocular hypotensive efficacy of netarsudil ophthalmic solution 0.02% over a 24-hour period: a pilot study","volume":"58","author":"Peace","year":"2017","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40123-020-00322-1","article-title":"A randomized, phase 2 study of 24-h efficacy and tolerability of netarsudil in ocular hypertension and open-angle glaucoma","volume":"10","author":"Peace","year":"2021","journal-title":"Ophthalmology Therapy"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0022|cit22","unstructured":"Rhopressa (netarsudil) ophthalmic solution www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208254Orig1s000TOC.cfm"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","article-title":"Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocular hypertension: a phase 2 study","volume":"226","author":"Sit","year":"2021","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD013817.pub2-BIB0025|cit25","first-page":"ARVO E","article-title":"Improvement of trabecular outflow facility by netarsudil ophthalmic solution in patients with primary open angle glaucoma or ocular hypertension","volume":"60","author":"Sit","year":"2019","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD013817.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD013817.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/aos.12599","article-title":"Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study","volume":"93","author":"Tanihara","year":"2015","journal-title":"Acta Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD013817.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD013817.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD013817.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","article-title":"Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study","volume":"2","author":"Walters","year":"2019","journal-title":"Ophthalmology Glaucoma"},{"issue":"13","key":"10.1002\/14651858.CD013817.pub2-BIB0031|cit31","first-page":"545","article-title":"Double-masked, randomized, dose response study of AR-13324 ophthalmic solution compared to latanoprost in patients with elevated intraocular pressure","volume":"55","author":"Dubiner","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"10","key":"10.1002\/14651858.CD013817.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00417-017-3727-5","article-title":"One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy","volume":"255","author":"Inazaki","year":"2017","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10384-018-0635-0","article-title":"Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma","volume":"63","author":"Komizo","year":"2019","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD013817.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1358\/dot.2018.54.8.2849627","article-title":"Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension","volume":"54","author":"Kopczynski","year":"2018","journal-title":"Drugs Today\u00a0"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0035|cit35","unstructured":"A study to assess the effect of rho-kinase inhibitor AR-12286 ophthalmic solution 0.5% and 0.7% in patients with uncontrolled advanced glaucoma with prior failed trabeculectomy or tube shunt clinicaltrials.gov\/show\/NCT02173223"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0036|cit36","unstructured":"Study of Rhopressa\u00ae for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension in a real-world setting clinicaltrials.gov\/ct2\/show\/NCT03808688"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/s41598-019-40255-9","article-title":"Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial","volume":"9","author":"Sakamoto","year":"2019","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmologica"},{"issue":"12","key":"10.1002\/14651858.CD013817.pub2-BIB0039|cit39","first-page":"ARVO E","article-title":"Specific clinical features of intraocular pressure-lowering effect in ripasudil (K-115): insights from 52-week phase 3 study","volume":"57","author":"Tanihara","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0040|cit40","unstructured":"One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000030126"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0041|cit41","unstructured":"Assessment report: Rhokiinsa (netarsudil) www.ema.europa.eu\/en\/documents\/assessment-report\/rhokiinsa-epar-public-assessment-report_en.pdf"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0042|cit42","unstructured":"Study of AR-13324 in patients with elevated intraocular pressure clinicaltrials.gov\/ct2\/show\/study\/NCT01528787"},{"issue":"15","key":"10.1002\/14651858.CD013817.pub2-BIB0043|cit43","first-page":"ARVO E","article-title":"Evaluation of AR-13324, a novel dual mechanism agent, in lowering of IOP in glaucoma and ocular hypertension","volume":"54","author":"Weiss","year":"2013","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0044|cit44","unstructured":"A clinical trial to check the effect, safety and tolerability of ripasudil hydrochloride hydrate eye drops 0.4% w\/v vs timolol maleate eye drops 0.5% w\/v in patients with ocular hypertension\/glaucoma ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=21731&EncHid=&userName=ripasudil"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0045|cit45","unstructured":"A study of netarsudil ophthalmic solution 0.02% w\/v vs timolol maleate eye drops 0.5% w\/v in treatment of elevated intraocular pressure in patient with open angle glaucoma or ocular hypertension ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=38394&EncHid=&userName=timolol maleate"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0046|cit46","unstructured":"A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 ophthalmic solution compared to GANFORT\u00ae (bimatoprost 0.03%\/timolol 0.5%) ophthalmic solution in subjects with elevated intraocular pressure (MERCURY 3) www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-001528-41-AT"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0047|cit47","unstructured":"Safety and efficacy study of PG324 (netarsudil\/latanoprost 0.02%\/0.005%) ophthalmic solution compared to GANFORT\u00ae ophthalmic solution in open angle glaucoma or ocular hypertension clinicaltrials.gov\/show\/NCT03284853"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0048|cit48","unstructured":"A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 ophthalmic solution compared to GANFORT\u00ae (bimatoprost 0.03%\/timolol 0.5% ophthalmic solution) in subjects with elevated intraocular pressure (MERCURY 3) www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-001528-41-ES"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0049|cit49","unstructured":"WP-1303 phase 3 comparison study www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?japicId=JapicCTI-194920"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0050|cit50","unstructured":"Efficacy of Rho-kinase inhibitor ophthalmic solution on bleb formation after trabeculectomy, a randomized parallel study upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000021996"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0051|cit51","unstructured":"Rhokiinsa \u2013 EMEA\/H\/C\/004583 www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rhokiinsa"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2015.04.029","article-title":"The aqueous humor outflow pathways in glaucoma: a unifying concept of disease mechanisms and causative treatment","volume":"95","author":"Braunger","year":"2015","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0053|cit53","first-page":"3","volume-title":"Progress in Brain Research","volume":"173","author":"Cedrone","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD013817.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","article-title":"Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement","volume":"119","author":"Chang","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","article-title":"Glaucoma treatment trends: a review","volume":"52","author":"Conlon","year":"2017","journal-title":"Canadian Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0056|cit56","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0057|cit57","unstructured":"What is a serious adverse event? www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0058|cit58","unstructured":"Novel drug approvals for 2017 www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2017"},{"issue":"5","key":"10.1002\/14651858.CD013817.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.preteyeres.2004.10.003","article-title":"Changes in aqueous humor dynamics with age and glaucoma","volume":"24","author":"Gabelt","year":"2005","journal-title":"Progress in Retinal and Eye Research\u00a0"},{"issue":"18","key":"10.1002\/14651858.CD013817.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: first global approval","volume":"74","author":"Garnock-Jones","year":"2014","journal-title":"Drugs"},{"issue":"10180","key":"10.1002\/14651858.CD013817.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial","volume":"393","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013817.pub2-BIB0062|cit62","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0063|cit63","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"10","key":"10.1002\/14651858.CD013817.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0065|cit65","unstructured":"Higgins JP Green S Chapter 16: Missing data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0066|cit66","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0067|cit67","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD013817.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","article-title":"Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits","volume":"39","author":"Isobe","year":"2014","journal-title":"Current Eye Research"},{"issue":"10108","key":"10.1002\/14651858.CD013817.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"Article ID 7079","DOI":"10.1155\/2017\/7079645","article-title":"Additive intraocular pressure-lowering effects of ripasudil with glaucoma therapeutic agents in rabbits and monkeys","volume":"2017","author":"Kaneko","year":"2017","journal-title":"Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD013817.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/jop.2017.0138","article-title":"The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans","volume":"34","author":"Kazemi","year":"2018","journal-title":"Journal of Ocular Pharmacology and Therapeutics\u00a0"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1874364101509010089","article-title":"Present and new treatment strategies in the management of glaucoma","volume":"9","author":"Kolko","year":"2015","journal-title":"Open Ophthalmology Journal"},{"issue":"6","key":"10.1002\/14651858.CD013817.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/0039-6257(80)90122-8","article-title":"The Framingham Eye study: introduction to the monograph","volume":"24","author":"Kreuger","year":"1980","journal-title":"Survey of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD013817.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMra0804630","article-title":"Primary open-angle glaucoma","volume":"360","author":"Kwon","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0076|cit76","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"e60831","DOI":"10.7554\/eLife.60831","article-title":"Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis","volume":"10","author":"Li","year":"2021","journal-title":"Elife"},{"issue":"1-2","key":"10.1002\/14651858.CD013817.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD013817.pub2-BIB0079|cit79","first-page":"6125","article-title":"Evaluation of the potential of AR-13324 and AR-13503 to Induce phospholipidosis","volume":"59","author":"Lin","year":"2018","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1350-9462(98)00011-1","article-title":"Functional morphology of the trabecular meshwork in primate eyes","volume":"18","author":"L\u00fctjen-Drecoll","year":"1999","journal-title":"Progress in Retinal and Eye Research"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0081|cit81","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2\u00a0(updated February\u00a02021). Cochrane, 2021 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","journal-title":"Eye"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Moher D Liberati A Tetzlaff J Altman DG The PRISMA Group Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement PLoS Medicine 2009 6 7 e1000097","DOI":"10.1371\/journal.pmed.1000097"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00417-019-04283-5","article-title":"Rho kinase inhibitors \u2013 a review on the physiology and clinical use in ophthalmology","volume":"257","author":"Moura-Coelho","year":"2019","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"Article ID 2646","DOI":"10.1155\/2017\/2646904","article-title":"Application of Rho kinase inhibitors for the treatment of corneal endothelial diseases","volume":"2017","author":"Okumura","year":"2017","journal-title":"Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ajo.2020.09.050","article-title":"Randomized, double-masked trial of netarsudil 0.02% ophthalmic solution for prevention of corticosteroid-Induced ocular hypertension","volume":"222","author":"Price","year":"2021","journal-title":"American Journal of \u00a0Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD013817.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"British Journal of Ophthalmology"},{"issue":"9774","key":"10.1002\/14651858.CD013817.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"\u00a0Quigley","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013817.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","article-title":"Drug-induced corneal epithelial changes","volume":"62","author":"Raizman","year":"2017","journal-title":"Survey of Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","article-title":"Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research","volume":"158","author":"Rao","year":"2017","journal-title":"Experimental Eye Research"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0091|cit91","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0092|cit92","unstructured":"WebPlotDigitizer Ankit Rohatgi"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0093|cit93","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from \u00a0training.cochrane.org\/handbook\/archive\/v6"},{"issue":"2","key":"10.1002\/14651858.CD013817.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/ICU.0b013e32834ff23e","article-title":"Current understanding of conventional outflow dysfunction in glaucoma","volume":"23","author":"Stamer","year":"2012","journal-title":"Current Opinion in Ophthalmology"},{"key":"10.1002\/14651858.CD013817.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD013817.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","article-title":"Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma","volume":"26","author":"Sturdivant","year":"2016","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"issue":"11","key":"10.1002\/14651858.CD013817.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD013817.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD013817.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.ophtha.2004.01.025","article-title":"Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye study","volume":"11","author":"Varma","year":"2004","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD013817.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","article-title":"Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes","volume":"24","author":"Wang","year":"2015","journal-title":"Journal of Glaucoma"},{"issue":"18","key":"10.1002\/14651858.CD013817.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD013817.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/jop.2018.0134","article-title":"Patient-reported nonadherence with glaucoma therapy","volume":"35","author":"Wolfram","year":"2019","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD013817.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013817","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","author":"Freiberg","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T19:04:50Z","timestamp":1731870290000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013817.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":103,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013817.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}